Singular

U2-S08. Inmunochemical methods development (Remote) OUTSTANDING

CAbS offers personalized development of immunoassays. Antibodies and other necessary immunoreagents can be synthesized.

The development of the immunoassay includes different stages:

1. Design of the immunoassay format, sample matrix, the sensibility and the working range. Identification of necessary reagents and their conditions to obtain optimal results.
2. Development Phase. Establishing assay parameters, for example the detection limit and working range. Evaluation of the effects of the matrix on the assay. Reproducibility study.
3. Assay validation. Evaluation of the stability and robustness of the reagents. Measurement of inter and intra-assay reproducibility, precision and specificity. Validation with blind samples. Assay platforms: ELISA, microarrays with different formats based on the detection of individual analytes or multiplexed assays.

U2-S07. Antibody purification (Remote) OUTSTANDING

The purification of the antibodies includes the isolation of the antibody from the serum (polyclonal antibodies) or culture supernatant from hybridoma cell lines (monoclonal antibodies). The services offers previous advise on the different possibilities for purification according to the needs of the user.

The methods of purification that we offer vary from crude methods (precipitation of the proteins from the sample including any antibody present) to general purification (purification by affinity of certain classes of antibodies without taking account of the specificity to the antigen) to specific (purification by affinity of the antibodies which join specifically to a definite antigen).

• Ammonium sulfate precipitation
• Protein A, protein G affinity purification
• Specific antigen affinity purification

U2-S06. Hybridoma cell culture antibody production (Remote) OUTSTANDING

Hybridoma cell culture in ultralow serum medium. We use CELLine™  Bioreactor Technologys to produce monoclonal antibodies.

U2-S05. Monoclonal Antibody development (Remote) OUTSTANDING

The mAb development contains the following phases:

1. Immunisation of mice, titre determination in the antiserum.
2. Cultivation of the myeloma cell line, cell fusion, selection in HAT medium and screening.
3. Cloning , screening and cultivation of positive cultures. Further cloning and obtaining stable clones.
4. Expansion and Cryo conservation of the selected clones. Delivery of cell culture supernatants and frozen hybridoma cells.

U2-S04. Polyclonal Antibody Production (Remote) OUTSTANDING

The service has a standard immunization protocol that includes monthly inoculations with Freund adjuvant during a period of 4 months. This protocol can be adapted to final project objective.

To determine the progress of the immune response, a bleed is taken after 10 days after the second immunization to obtain antiserum and the titer is determined through ELISA.

Among the controls is included obtaining preimmune serum from the animals obtained from the blood previously to the first injection. At the end of the process 50-70 mL of hyperimmune serum is obtained per animal from final production bleed.